U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07777900) titled 'Glycated Albumin Monitoring' on May 06, 2025.
Brief Summary: The goal of this observational study is to learn if the short-term glucose marker (glycated albumin) works as well or better than CGM and/or hemoglobin A1c to indicate to providers that a change in medication is working to improve patient's blood sugar control.
Participants will have a blood draw at baseline (when their provider is making a change in medication to treat their diabetes) and also every 4 weeks until the next provider visit. At the end of the study, researchers will compare the time (days, weeks) to see a change in blood glucose control with each of the mark...